Bio-Techne Corporation (TECH)
52.60
1.88 (3.71%)
At close: Apr 14, 2025, 3:38 PM
3.71% (1D)
| Bid | 52.57 |
| Market Cap | 8.32B |
| Revenue (ttm) | 1.2B |
| Net Income (ttm) | 158.14M |
| EPS (ttm) | 0.98 |
| PE Ratio (ttm) | 53.67 |
| Forward PE | 33.09 |
| Analyst | Hold |
| Ask | 52.65 |
| Volume | 1,304,960 |
| Avg. Volume (20D) | 1,865,900 |
| Open | 51.47 |
| Previous Close | 50.72 |
| Day's Range | 50.94 - 52.74 |
| 52-Week Range | 46.44 - 85.57 |
| Beta | 1.45 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene ther...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 1989
Employees 3,100
Stock Exchange NASDAQ
Ticker Symbol TECH
Website https://www.bio-techne.com
Analyst Forecast
According to 8 analyst ratings, the average rating for TECH stock is "Hold." The 12-month stock price forecast is $80, which is an increase of 52.09% from the latest price.
Stock ForecastsNext Earnings Release
Bio-Techne Corporation is scheduled to release its earnings on Apr 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+3.72%
Bio-Techne shares are trading higher after the com...
Unlock content with
Pro Subscription
4 months ago
+4.36%
Bio-Techne shares are trading higher after Gemini Bioproducts acquired the company's product rights and inventory of selected fetal bovine serum.
